anti-CD7 PEBL-CAR T cells / National University Hospital Singapore, National University of Singapore - LARVOL DELTA

Promising cell therapy offers hope for relapsed or refractory T-cell leukemia (Nat Med, Medical Xpress) - P1 | N=20 | CARTALL (NCT05043571) | "A new cell therapy, targeting CD7 in leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment options. Published in the journal Nature Medicine...this therapy was given to 17 patients between April 2019 and October 2023 at the National University Hospital (NUH)...Notably, 16 of the 17 patients achieved complete remission within one month, and leukemic cells became undetectable even with ultra-sensitive flow cytometry tests that can detect one leukemia cell in the background of 10,000 normal cells, developed by Elaine Coustan-Smith's laboratory at NUS Medicine....The treatment was well-tolerated, and side effects were mild, given the fact that all patients enrolled had a high tumor burden and had received prolonged and intensive treatment prior to CAR-T therapy."

P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

Promising cell therapy offers hope for relapsed or refractory T-cell leukemia (Nat Med, Medical Xpress) - P1 | N=20 | CARTALL (NCT05043571) | "A new cell therapy, targeting CD7 in leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment options. Published in the journal Nature Medicine...this therapy was given to 17 patients between April 2019 and October 2023 at the National University Hospital (NUH)...Notably, 16 of the 17 patients achieved complete remission within one month, and leukemic cells became undetectable even with ultra-sensitive flow cytometry tests that can detect one leukemia cell in the background of 10,000 normal cells, developed by Elaine Coustan-Smith's laboratory at NUS Medicine....The treatment was well-tolerated, and side effects were mild, given the fact that all patients enrolled had a high tumor burden and had received prolonged and intensive treatment prior to CAR-T therapy."

P1 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia